Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are three stocks where Wall Street’s positive outlook is supported by strong fundamentals.

Xylem (XYL)

Consensus Price Target: $158.41 (31% implied return)

Formed through a spinoff, Xylem (NYSE: XYL) manufactures and services engineered products across a wide variety of applications primarily in the water sector.

Why Does XYL Stand Out?

1. Annual revenue growth of 13.1% over the last five years was superb and indicates its market share increased during this cycle
2. Incremental sales significantly boosted profitability as its annual earnings per share growth of 19.8% over the last five years outstripped its revenue performance
3. Free cash flow margin grew by 3.7 percentage points over the last five years, giving the company more chips to play with

At $120.91 per share, Xylem trades at 22.3x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

Rocket Lab (RKLB)

Consensus Price Target: $89.88 (26.3% implied return)

Becoming the first private company in the Southern Hemisphere to reach space, Rocket Lab (NASDAQ: RKLB) offers rockets designed for launching small satellites.

Why Could RKLB Be a Winner?

1. Annual revenue growth of 56.9% over the last two years was superb and indicates its market share increased during this cycle
2. Market share will likely rise over the next 12 months as its expected revenue growth of 41.6% is robust
3. Returns on capital are increasing as management’s prior bets are starting to bear fruit

Rocket Lab is trading at $71.15 per share, or 46.3x forward price-to-sales. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.

Hamilton Lane (HLNE)

Consensus Price Target: $172.86 (76.5% implied return)

With over $100 billion in assets under management and supervision, Hamilton Lane (NASDAQ: HLNE) is an investment management firm that specializes in private markets, offering advisory services and fund solutions to institutional and private wealth investors.

Why Is HLNE a Top Pick?

1. Market share has increased this cycle as its 24.8% annual revenue growth over the last two years was exceptional
2. Additional sales over the last two years increased its profitability as the 26.6% annual growth in its earnings per share outpaced its revenue
3. ROE punches in at 35.6%, illustrating management’s expertise in identifying profitable investments

Hamilton Lane’s stock price of $97.93 implies a valuation ratio of 17.1x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Stocks We Like Even More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.